Mirati Therapeutics, Inc.

NasdaqGS:MRTX Stock Report

Market Cap: US$4.1b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Mirati Therapeutics Dividends and Buybacks

Dividend criteria checks 0/6

Mirati Therapeutics does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-8.4%

Buyback Yield

Total Shareholder Yield-8.4%
Future Dividend Yield0%
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Payout ration/a

Recent dividend and buyback updates

No updates

Recent updates

We Think Mirati Therapeutics (NASDAQ:MRTX) Needs To Drive Business Growth Carefully

Oct 05
We Think Mirati Therapeutics (NASDAQ:MRTX) Needs To Drive Business Growth Carefully

Is Mirati Therapeutics (NASDAQ:MRTX) In A Good Position To Invest In Growth?

Jun 22
Is Mirati Therapeutics (NASDAQ:MRTX) In A Good Position To Invest In Growth?

Need To Know: Analysts Are Much More Bullish On Mirati Therapeutics, Inc. (NASDAQ:MRTX) Revenues

May 17
Need To Know: Analysts Are Much More Bullish On Mirati Therapeutics, Inc. (NASDAQ:MRTX) Revenues

We Think Mirati Therapeutics (NASDAQ:MRTX) Needs To Drive Business Growth Carefully

Feb 01
We Think Mirati Therapeutics (NASDAQ:MRTX) Needs To Drive Business Growth Carefully

Some Analysts Just Cut Their Mirati Therapeutics, Inc. (NASDAQ:MRTX) Estimates

Dec 09
Some Analysts Just Cut Their Mirati Therapeutics, Inc. (NASDAQ:MRTX) Estimates

We Think Mirati Therapeutics (NASDAQ:MRTX) Can Afford To Drive Business Growth

Oct 08
We Think Mirati Therapeutics (NASDAQ:MRTX) Can Afford To Drive Business Growth

Is There An Opportunity With Mirati Therapeutics, Inc.'s (NASDAQ:MRTX) 30% Undervaluation?

Sep 11
Is There An Opportunity With Mirati Therapeutics, Inc.'s (NASDAQ:MRTX) 30% Undervaluation?

Mirati: A Potential Blockbuster Stock, Will Need Patience

Sep 08

Mirati jumps 11% as Amgen meets key goal for rival cancer drug

Aug 31

Mirati gains as Amgen posts new combination data for rival cancer drug

Aug 08

Need To Know: Analysts Are Much More Bullish On Mirati Therapeutics, Inc. (NASDAQ:MRTX) Revenues

Aug 08
Need To Know: Analysts Are Much More Bullish On Mirati Therapeutics, Inc. (NASDAQ:MRTX) Revenues

Mirati: Not Looking Good In 2022, But Stronger Prospects In 2-3 Years

Jun 21

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if MRTX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MRTX's dividend payments have been increasing.

Dividend Yield vs Market

Mirati Therapeutics Dividend Yield vs Market
How does MRTX dividend yield compare to the market?
SegmentDividend Yield
Company (MRTX)n/a
Market Bottom 25% (US)1.5%
Market Top 25% (US)4.5%
Industry Average (Biotechs)2.5%
Analyst forecast (MRTX) (up to 3 years)0%

Notable Dividend: Unable to evaluate MRTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MRTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate MRTX's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as MRTX has not reported any payouts.

Discover strong dividend paying companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/01/23 00:57
End of Day Share Price 2024/01/22 00:00
Earnings2023/09/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Mirati Therapeutics, Inc. is covered by 31 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Huidong WangBarclays
George FarmerBMO Capital Markets Equity Research
Jason Matthew GerberryBofA Global Research